Press Releases
These are news releases that are related to our Investor efforts. Releases are listed in chronological order and are archived by year. Sign-up to receive news as it is released using the email and RSS tools below.
-
Sep 30, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that Jennifer Buell,...
-
Aug 28, 2019FDA acceptance of IND filing for AGEN1223; triggers cash milestone
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has...
-
Aug 21, 2019Invented by Agenus, licensed to Gilead, GS-1423 is a bi-functional antibody designed to block tumor escape mechanisms
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced a manufacturing agreement with...
-
Aug 8, 2019- FDA acceptance of IND filing for AGEN2373 triggers payment and clears path to begin clinical trials
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1 and cancer vaccines, announced today that the FDA has...
-
Aug 8, 2019- Enrollment of CTLA-4 & PD-1 trials on track; data expected 2H2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, adoptive cell therapies1, and cancer vaccines provided corporate updates and reported...
-
Aug 6, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its second quarter 2019 financial results before the market...
-
Jul 18, 2019The appointment comes as Agenus is preparing for its first BLA filing in 2020 and evolving towards a commercial company
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a broad pipeline of novel clinical and preclinical stage checkpoint antibodies, cell therapies and neoantigen vaccines, today announced...
-
Jun 13, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, invites investors and the general...
-
May 9, 2019- Gilead partnership yields $150M & first milestone of $7.5M
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, provided corporate updates and reported...
-
May 3, 2019
Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, will release its first quarter 2019...